Healthcare / Pharmaceutical RetailersJakartaID
$181.00
+6.00 (+3.43%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-19.2B · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$304.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-13.2%
↓Gross Margin
41.1%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.0%
FCF CAGR
—
FCF margin
6.2%
FCF / Net income
-0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $363.57B · net income $-28.78B · FCF $22.49B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $363.57B | $363.57B | $412.07B | $441.14B | $398.73B |
| Net Income | $-28.78B | $-28.78B | $5.01B | $15.34B | $16.58B |
| EPS | -17.09 | -17.09 | 2.98 | 9.10 | 9.84 |
| Gross Margin | 41.1% | 41.1% | 45.3% | 42.9% | 45.5% |
| Operating Margin | -6.4% | -6.4% | 4.6% | 7.3% | 8.6% |
| Net Margin | -7.9% | -7.9% | 1.2% | 3.5% | 4.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 1.37 | 1.37 | 1.53 | 1.57 | 1.39 |
| Cash Flow | |||||
| Free Cash Flow | $22.49B | $22.49B | $-37.33B | $-19.24B | $-1.11B |
| Returns | |||||
| ROE | -13.2% | -13.2% | 2.0% | 6.3% | 9.4% |
| Growth & Yield | |||||
| Revenue Growth | -11.8% | -11.8% | -6.6% | 10.6% | — |
| EPS Growth | -674.0% | -674.0% | -67.3% | -7.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.0%
Start / end P/E
n/dx → n/dx
EPS bridge
2.98 → -17.09
Residual
-22.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.